InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease.
Mechanistic modeling will be leveraged to simulate pharmacokinetics (PK) and target occupancy (TO) in cerebrospinal fluid (CSF) of NIDB-3101 being developed by discoveric bio alpha.
Jean-Philippe Courade, CSO of discoveric bio alpha, highlights, “We are excited to implement InSysBio’s solutions and wide-ranging modeling experience to enhance the design of preclinical study of NIDB-3101. We hope mechanistic modeling will facilitate accurate dose selection thus accelerating and optimizing further development of our antibody”.
Oleg Demin Jr, Scientific Director, InSysBio, comments on the new project, “Our cutting-edge mechanistic modeling approach along with our expertise in modeling of therapeutic antibodies enable us to efficiently develop the PK/TO model based on the published data for other mAbs. We look forward to apply our knowledge and software to support optimization of the experiment design”.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
About discoveric bio alpha
discoveric bio alpha is a privately owned company part of a group of three separate companies dedicated to the development of novel therapeutics for the treatment of Alzheimer’s Disease, Neuroinflammation and Antimicrobial Resistant infections. It is located in Pfäffikon, Switzerland. For more information, visit https://www.discovericbio.com/
| ← | October 2022 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
1.
12 Oct 2022 16:07
InSysBio to take part in ACoP13
InSysBio announces its participation in the Thirteenth American Conference on Pharmacometrics (ACoP13) which is to be held in person from October 30th to November 2nd, 2022, at the Gaylord Rockies Resort & Convention Center in Aurora, Colorado. InSysBio team is going to present 7 posters in frames of the Conference
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
1.
25 Oct 2022 14:41
InSysBio to present its ePoster at ECTRIMS 2022
InSysBio team is going to present its poster in frames of 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis which is to be held October 26-28, Amsterdam, the Netherlands. The ePoster is going to be presented in frames of "Pathology and pathogenesis of MS - Neurodegeneration" ePoster Area, October 26
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
